Clinical Trial Update: Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing olaparib plus pembrolizumab to chemotherapy plus pembrolizumab after induction with first-line chemotherapy in triple-negative breast ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Triple Negative Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2024-02-14